Manon Pillai
Overview
Explore the profile of Manon Pillai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
219
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shohdy K, Atherton J, Longland J, Alison J, Pillai M, Thistlethwaite F
Oncoimmunology
. 2025 Feb;
14(1):2462386.
PMID: 39981665
Specific shared HLA-I alleles were linked to the response to immune checkpoint blockade (ICB). We aimed to identify the HLA-A subtypes associated with maximum benefit from ICB. We compiled a...
2.
Waddell T, Pillai M, Armitage K, Graham D, Moran M, Dilleen M, et al.
Future Oncol
. 2024 Oct;
20(33):2547-2558.
PMID: 39382446
Renal cell carcinoma (RCC) is the seventh commonest cancer in the UK, where first-line (1L) sunitinib and second-line (2L) axitinib are treatment options. Retrospective, non-interventional data from the Christie NHS...
3.
Shohdy K, Pillai M, Guest R, Rothwell D, Kirillova N, Chow S, et al.
EJHaem
. 2023 Aug;
4(3):882-885.
PMID: 37601889
The persistence and reactivity of CAR T cells were enhanced by adding co-stimulatory domains, which is the basis of currently approved CAR-T cell therapies. However, this comes at the expense...
4.
Bogatu A, Wysocka M, Wysocki O, Butterworth H, Pillai M, Allison J, et al.
J Biomed Inform
. 2023 Apr;
142:104367.
PMID: 37105509
Cytokine release syndrome (CRS), also known as cytokine storm, is one of the most consequential adverse effects of chimeric antigen receptor therapies that have shown otherwise promising results in cancer...
5.
Pillai M, Jiang Y, Lorigan P, Thistlethwaite F, Thomas M, Kirillova N, et al.
Am J Cancer Res
. 2022 Sep;
12(8):3967-3984.
PMID: 36119832
Nonselected autologous tumor-infiltrating lymphocytes (TILs) may provide advantages over other treatments for solid tumors, including checkpoint inhibitor-refractory melanoma. This retrospective analysis reports a single-center experience of nonselected autologous TILs derived...
6.
Lagan J, Naish J, Fortune C, Campbell C, Chow S, Pillai M, et al.
Diagnostics (Basel)
. 2022 Jun;
12(6).
PMID: 35741162
High dose interleukin-2 (IL-2) is known to be associated with cardiopulmonary toxicity. The goal of this study was to evaluate the effects of high dose IL-2 therapy on cardiopulmonary structure...
7.
Venugopal B, Pillai M, Powles T, Savage P, Michael A, Fife K, et al.
Clin Genitourin Cancer
. 2021 Nov;
20(1):94-94.e10.
PMID: 34802966
Background: Cabozantinib monotherapy is approved in the UK for patients with treatment-naïve intermediate- or poor-risk advanced renal cell carcinoma (aRCC), or patients who received prior vascular endothelial growth factor-targeted therapy....
8.
Pillai M, Davies M, Thistlethwaite F
Ther Adv Vaccines Immunother
. 2020 Oct;
8:2515135520944355.
PMID: 33015538
Advanced Therapy Medicinal Products (ATMPs) comprise novel cell, tissue and gene therapies and offer the potential of durable remissions for diseases where there is a high unmet clinical need. Once...
9.
Azizi A, Pillai M, Thistlethwaite F
Curr Opin Oncol
. 2019 Jul;
31(5):430-438.
PMID: 31335828
Purpose Of Review: The remarkable and durable clinical responses seen in certain solid tumours using checkpoint inhibitors and in haematological malignancies using chimeric antigen receptor (CAR) T therapy have led...
10.
Thistlethwaite F, Gilham D, Guest R, Rothwell D, Pillai M, Burt D, et al.
Cancer Immunol Immunother
. 2017 Jun;
66(11):1425-1436.
PMID: 28660319
The primary aim of this clinical trial was to determine the feasibility of delivering first-generation CAR T cell therapy to patients with advanced, CEACAM5 malignancy. Secondary aims were to assess...